The effect of pirfenidone on the mortality risk score in IPF

The effect of pirfenidone on the mortality risk score in IPF - The effect of pirfenidone on the mortality risk score in IPF

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008541

Enrollment

Registered

2012-07-30

Start date

2012-07-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

idiopathic pulmonary fibrosis

Interventions

pirfenidone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. diagnosis of IPF according to the 2011 ATS/ERS/JRS/ALAT statement 2. Age >= 20 3. No infections, rapid deterioration, acute exacerbation, etc. in previous 3 months 4. No change of treatments for IPF in previous 3 months 5. mortality risk score >= 22 6. Having underwent pulmonary function test 6-12 months before the registration 7. written informed consent

Exclusion criteria

Exclusion criteria: 1. Diagnosis of malignancies 2. Unable to undergo pulmonary function test and 6-min walk test 3. Already taking pirfenidone 4. A history of severe toxicity of pirfenidone 5. Undergoing long-term oxygen therapy at rest

Design outcomes

Primary

Measure	Time frame
mortality risk score	—

Secondary

Measure	Time frame
1. pulmonary function test 2. 6-min walk test 3. dyspnea 4. chest HRCT findings	—

Countries

Japan

Contacts

Public ContactOsamu Nishiyama, MD

Kinki University Faculty of Medicine Department of Respiratory Medicine and Allergology

nishi-o@med.kindai.ac.jp072-366-0221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026